Protein and monoclonal antibody (mAb) biopharmaceuticals form a major part of the growing biologics drug market. MAb treatment is amongst the most effective methods of diagnosis and treatment of a broad range of diseases. The need for innovative and efficient analytic tools during development and production of these products is essential to detect, characterize and quantify impurities structural variants and modifications, and to monitor product stability.
United States
